|
Aug 1
|
Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges
|
|
Jul 31
|
Iovance Biotherapeutics (IOVA) Names Corleen Roche as New CFO
|
|
Jul 30
|
Is Iovance Biotherapeutics Stock Due for a Big Rally?
|
|
Jul 29
|
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
|
|
Jul 24
|
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
|
|
Jul 23
|
BC-Most Active Stocks
|
|
Jul 21
|
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside
|
|
Jul 15
|
Sector Update: Health Care Stocks Mixed Premarket Tuesday
|
|
Jul 15
|
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
|
|
Jul 14
|
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
|
|
Jul 10
|
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
|
|
Jun 29
|
Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data
|
|
Jun 26
|
Iovance Biotherapeutics (NasdaqGM:IOVA) Announces CFO Resignation
|
|
Jun 20
|
Gene Therapy Stocks Fall Amid More Turmoil at FDA
|
|
Jun 10
|
Iovance Biotherapeutics to Present at Upcoming Conference
|
|
May 23
|
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma
|
|
May 22
|
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
|
|
Apr 7
|
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
|
|
Apr 4
|
Iovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market Correction
|
|
Mar 12
|
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
|